Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
Bio-Rad Diabetes Division

Biomarker Identified for Smoker’s Lung Cancer

By Labmedica International staff writers
Posted on 03 Oct 2013
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
A specific pair of proteins may be a successful prognostic biomarker for identifying smoking-related lung cancers, especially pulmonary adenocarcinoma.

The protein achaete-scute homolog 1 (ASCL1) is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation and as a potential prognostic biomarker remains unclear.

Scientists at the Mayo Clinic (Rochester, MN, USA) examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome, and smoking status and compared with expression of traditional NE markers. ASCL1 messenger ribonucleic acid (mRNA) expression was found almost exclusively in smokers with adenocarcinoma, in contrast to nonsmokers and other lung cancer subtypes.

Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the rearranged during transfection (RET) oncogene in ASCL1-positive tumors (ASCL1+) compared with ASCL1− tumors. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and the cluster of differentiation CD56 and the neural cell adhesion molecule (CD56/NCAM).

High levels of RET expression in ASCL1+, but not in ASCL1- tumors, was associated with significantly shorter overall survival in stage 1 and in all adenocarcinomas. RET protein expression by IHC had an association with overall survival in the context of ASCL1 expression. When scientists blocked the ASCL1 protein in lung cancer-cell lines expressing both genes, the level of RET decreased and tumor growth slowed. This leads them to believe this mechanism will be a promising target for potential drugs and a strong candidate for clinical trials.

George Vasmatzis, PhD, molecular medical scientist and senior author on the study, said “This is exciting because we’ve found what we believe to be a ‘drugable target’ here. It’s a clear biomarker for aggressive adenocarcinomas. These are the fast-growing cancer cells found in smokers’ lungs.” The study was published on September 16, 2013, in the journal Oncogene.

Related Links:
Mayo Clinic



DiagCor Bioscience
77 ELEKTRONIKA
PURITAN MEDICAL
comments powered by Disqus
Sekisui Diagnostics

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Pathology

view channel
Image: The Isolation by Size of Epithelial Tumor cells (ISET) technology (Photo courtesy of Rarecells Diagnostics).

Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer

Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer and migration of circulating tumor cells (CTCs) into the blood stream is an early event that occurs during carcinogenesis.... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.